Tofacitinib
Back to searchMolecule Structure
Scientific Name
Tofacitinib
Description of the Drug
Tofacitinib is a Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08895
http://www.drugbank.ca/drugs/DB08895
Brand Name(s)
Not Available
Company Owner(s)
Zydus Pharmaceuticals Usa Inc, Pf Prism Cv, Ajanta Pharma Ltd, Pfizer Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Janus Kinase (JAK) | PROTEIN FAMILY | INHIBITOR | CHEMBL2363062 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL322753 | |||
DrugBank | DB08895 | |||
PubChem: Thomson Pharma | 14898931 | 16573063 | ||
PubChem | 9926791 | |||
LINCS | LSM-1227 | |||
Nikkaji | J2.740.060D | |||
PDBe | MI1 | |||
BindingDB | 50193995 | |||
EPA CompTox Dashboard | DTXSID90197271 | |||
DrugCentral | 4713 | |||
Brenda | 155478 | 77457 | 27073 | 154591 |
Guide to Pharmacology | 5677 | |||
rxnorm | TOFACITINIB | TOFACITINIB CITRATE | XELJANZ | |
ChEBI | 71200 | |||
ZINC | ZINC000003818808 |